Latest Articles and Analysis

A proposed OMB rule would let political appointees veto or cancel federal research grants, dismantling the peer-review system and targeting the disparate-impact analysis that maps where HIV concentrates and why. For people living with HIV, that research is the foundation of Ending the HIV Epidemic. The comment period closes July 13.

On April 24, 2026, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued a Dear Colleague letter that withdraws federal funding eligibility from fentanyl test strips, sterile...

For a long time, I thought advocacy meant surviving the next appointment. I thought it meant learning how to explain my pain better, how to prepare for another referral visit, how to justify why I...

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

European price controls demonstrate MFN policy risks: delayed access, treatment rationing, and pharmaceutical innovation collapse.

RFK Jr's dismantling of CDC scientific leadership replaces expertise with anti-vaccine ideology and predetermined policy conclusions.

Elimination of health equity research funding undermines evidence base for addressing healthcare disparities and structural inequalities.

Gamification as innovative approach to HIV prevention education for youth.

Grindr's at-home STI testing kits address barriers to sexual health testing.

Innovative approaches to improve HIV care transitions for people exiting incarceration.

ADAP coverage gaps for long-acting injectable HIV treatments and equity implications.

Major HIV research breakthroughs from CROI 2024: long-acting treatments and prevention advances.

US Trans Survey provides critical data on transgender healthcare, discrimination, and social determinants.

European Commission approves lenacapavir, a novel six-month injectable for treatment-resistant HIV.

Access Health Louisiana uses animated series and radio to educate communities on HIV, HCV, and public health.

FDA reclassifies HCV testing to reduce regulatory burden and enable new test makers to enter market.

Nobel laureate's HCV vaccine development targeting 2029 offers hope alongside access equity challenges.

Explores technology innovations in HIV care including mobile apps and drone pharmacy delivery.

Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.

COVID-19 vaccine development spurs reflection on 35-year HIV vaccine search and mRNA technology advances.